Resumo

TORRES, Joana; CRAVO, Marília  e  COLOMBEL, Jean-Frédéric. Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Port J Gastroenterol [online]. 2016, vol.23, n.3, pp.153-161. ISSN 2341-4545.  https://doi.org/10.1016/j.jpge.2015.11.004.

The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.

Palavras-chave : Inflammatory Bowel Diseases/drug therapy; Tumor Necrosis Factor-Alpha/antagonists and inhibitors; Tumor Necrosis Factor-Alpha/therapeutic use; Withholding Treatment.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )